Trial Profile
A retrospective study, single center evaluating efficacy and safety of Sorafenib in patients with radioiodine-refractory advanced thyroid cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 13 May 2016 New trial record